Last updated: 11/04/2018 04:53:27
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskREDUCE
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
Trial description: This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at an increased risk for prostate cancer. Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits), and a prostate biopsy will be performed at 2 and 4 years of treatment.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:
Number of participants with biopsy-detectable prostate cancer at Years 2 and 4 (crude rate approach)
Timeframe: Years 1-2, Years 3-4, and Overall (Years 1-4)
Number of participants with biopsy-detectable prostate cancer at Years 2 and 4 (modified crude rate approach)
Timeframe: Years 1-2, Years 3-4, and Overall (Years 1-4)
Number of participants with biopsy-detectable prostate cancer at Years 2 and 4 (restricted crude rate approach)
Timeframe: Years 1-2, Years 3-4, and Overall (Years 1-4)
Secondary outcomes:
Number of participants with the indicated Gleason score at diagnosis
Timeframe: Baseline to Year 4
Number of participants with HGPIN, ASAP, and prostate cancer at biopsy
Timeframe: Baseline to Year 4
Volume of HGPIN at biopsy
Timeframe: Baseline to Year 4
Percentage of core involved at diagnosis
Timeframe: Baseline to Year 4
Number of cancer-positive cores
Timeframe: Baseline to Year 4
Treatment alteration score
Timeframe: Baseline to Year 4
Number of participants undergoing intervention (surgical and non-surgical) for prostate cancer treatment
Timeframe: Baseline to Year 4
Adjusted mean change from baseline in the International Prostate Symptom Score (IPSS) at Month 48
Timeframe: Baseline to Year 4 (Month 48)
Adjusted mean percentage change from baseline in prostate volume at Months 24 and 48
Timeframe: Baseline, Month 24, and Month 48
Adjusted mean change from baseline in maximum urinary flow (Qmax) at Months 12, 24, 36, and 48
Timeframe: Baseline and Months 12, 24, 36, and 48
Number of participants starting alpha blockers to control benign prostatic hyperplasia (BPH) symptoms
Timeframe: Years 1-2, Overall (Years 1-4)
Number of participants with at least one event of acute urinary retention (AUR)
Timeframe: Years 1-2 and Overall (Years 1-4)
Number of participants with at least one urinary tract infection (UTI)
Timeframe: Years 1-2, Years 3-4, and Overall (Years 1-4)
Number of participants with post-biopsy macroscopic hematuria
Timeframe: Baseline to Year 4
Number of participants with post-biopsy macroscopic hematospermia
Timeframe: Baseline through Year 4
Overall Survival
Timeframe: From time informed consent is signed to 4-month Safety Follow-Up period
Adjusted mean change from baseline in the Benign Prostatic Hypertrophy (BPH) Impact Index (BII) at Month 48
Timeframe: Baseline and Month 48
Adjusted mean change from baseline in The Medical Outcomes Study Sleep Problems Index 6-item Standard version (MOS Sleep-6S) at Month 48
Timeframe: Baseline and Month 48
Adjusted mean change from baseline in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH CPSI) at Month 48
Timeframe: Baseline and Month 48
Adjusted mean change from baseline in Quality of Life Question 8 (QOL Q8) at Month 48
Timeframe: Baseline and Month 48
Adjusted mean change from baseline in the Problem Assessment Scale of the Sexual Function Index (PASSFI) at Month 48
Timeframe: Baseline and Month 48
Number of participants with the indicated serum dihydrotestosterone (DHT) concentration at Month 48
Timeframe: Month 48
Mean change from baseline in testosterone at Month 48
Timeframe: Baseline and Month 48
Interventions:
Enrollment:
8231
Primary completion date:
2009-11-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
A. K. Kader, J. Sun, B. H. Reck, P. J. Newcombe, Seong-Tae Kim, Tao Jin, Zheng Zhang, Sha Tao, Greg T. Platek, Colin F. Spraggs, John C. Whittaker, Vincent E. Mooser, John D. McConnell, S. Lilly Zheng, Lynn D. Condreay, Roger S. Rittmaster, Jianfeng Xu.. Potential Impact of Adding Genetic Markers to Clinical Parameters in Predicting Prostate Biopsy Outcomes in Men Following an Initial Negative Biopsy: Findings from the REDUCE Trial. [Eur Urol [E-Pub 11 May]]. 2012;
Aubin SMJ, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. [J Urol]. 2010;184(4):1947-52.
Chenwei Wu; Daniel M. Moreira; Leah Gerber; Roger S. Rittmaster; Gerald L. Andriole; Stephen J. Freedland. DIABETES AND PROSTATE CANCER RISK IN THE REDUCE TRIAL. [Prostate Cancer Prostatic Dis]. 2011;14(4):326-31.
Claus G. Roehrborn, J. Curtis Nickel, Gerald L. Andriole, R. Paul Gagnier, Libby Black, Tim Wilson, Roger S. Rittmaster . Dutasteride improves the outcomes of benign prostatic hyperplasia: a secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. [Urology]. 2011;73(3):641-6.
David G. Bostwick, Junqi Qian, Krystyna Drewnowska, Stephen Varvel, Kathleen C. Bostwick, Michael Marberger, Roger S. Rittmaster . Prostate Needle Biopsy Quality in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Study: Worldwide Comparison of the Improvement with Investigator Training and Centralized Laboratory Processing. Urology. 2009;Nov 24:
David G. Bostwick, Junqi Qian, Krystyna Drewnowska, Stephen Varvel, Kathleen C. Bostwick, Michael Marberger, and Roger S. Rittmaster. REDUCE 4yr: Pathology, RP (Prostate Needle Biopsy Quality in Reduction by Dutasteride of Prostate Cancer Events Study: Worldwide Comparison of Improvement With Investigator Training and Centralized Laboratory Processing). [Urology]. 2010;75(6):1406-11.
E. David Crawford, Gerald Andriole, Michael Marberger, Roger Rittmaster. Reduction in the risk of prostate cancer: future directions after PCPT. Urology. 2009;Dec 24:
G Andriole, D Bostwick, O Brawley, L Gomella, M Marberger, F Montorsi, C Pettaway, T Tammela, C Teloken, D Tindall, M Somerville, I Fowler and R Rittmaster on behalf of the REDUCE Study Group. Risk reduction in men at increased risk: outcomes of the REduction by Dutasteride of prostate Cancer Events (REDUCE) trial. [N Engl J Med]. 2010;362(13):1192-202.
Gerald L. Andriole on behalf of the REDUCE study group. The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study. [Journal of Urology]. 2011;185(1):126-131.
Gerald L. Andriole, David G. Bostwick, Otis W. Brawley, Leonard G. Gomella, Michael Marberger, Francesco Montorsi, Curtis A. Pettaway, Teuvo L. Tammela, Claudio Teloken, Donald J. Tindall, Matthew C. Somerville, Timothy H. Wilson, Ivy L. Fowler, Roger S. Rittmaster. Effect of Dutasteride on the Risk of Prostate Cancer. N Engl J Med. 2010;362:1192-202
J. Curtis Nickel, Claus Roehrborn, Francesco Montorsi,Timothy Wilson, Roger S. Rittmaster. DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION OF DUTASTERIDE IN CANCER EVENTS) STUDY. [J Urol]. 2011;186(4):1313-8.
Jean-Alfred Thomas, II, Leah Gerber, Lionel Banez, Daniel Moreira,Ramiro Castro, Gerald L. Andriole and Stephen J. Freedland. Prostate Cancer Risk in Men with Prostate and Breast Cancer Family History: Results from the REDUCE study. [J Intern Med [Epub Dec 28 2011]]. 2011;
Michael Marberger, John D. McConnell, Ivy Fowler, Gerald L. Andriole, David G. Bostwick, Matthew C. Somerville, Roger S. Rittmaster. Biopsy Misidentification Identified by DNA Profiling in a Large Multicenter Trial. [J Clin Oncol]. 2011;29(13):1744-9.
Michael Marberger, Stephen J. Freedland, Gerald L. Andriole, Mark Emberton, Curtis A. Pettaway, Francesco Montorsi, Claudio Teloken, Roger S. Rittmaster, Matthew Somerville and Ramiro Castro. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. [BJU Int]. 2011;109(8):1162-1169.
Michael Marberger, Tim Wilson, Roger Rittmaster. Low serum testosterone levels are poor predictors of sexual dysfunction . [BJU Int]. 2011;108(2):256-62.
Michael W. Kattan, Stephanie R. Earnshaw, Cheryl L. McDade, Libby K. Black, Gerald L. Andriole. Cost-Effectiveness of Chemoprevention with Dutasteride Based on Results from the REDUCE Clinical Trial . [Appl Health Econ Health Policy]. 2011;9(5):305-15.
Muller RL, Gerber L, Moreira DM, Andriole G, Castro R, Freedland SJ. Baseline Serum Testosterone and DHT Levels and the Risk of Prostate Cancer Detection in the Placebo Arm of the REDUCE Trial. [Eur Urol [E-pub 18 May]]. 2012;
Newcombe PJ, Reck BH, Sun J, Platek GT, Verzill Ci, Karim Kader A, Kim S-T, Jin T, Zhang Z, Zheng SL, Condreay LD et al.. A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. [Genetics Epidemiology]. 2012;36(1):71-83.
Sheila M. J. Aubin, Jennifer Reid, Mark J. Sarno, Amy Blase, Jacqueline Aussie, Harry Rittenhouse, Roger S. Rittmaster, Gerald L. Andriole, Jack Groskopf. Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial . [Urology]. 2011;78(2):380-5.
Stephen J. Freedland, Leah Gerber, Lionel Banez, Daniel Moreira, Gerald L. Andriole, and Roger S. Rittmaster on behalf of the REDUCE Study Group. Statin Use and the Risk of Prostate Cancer and High-grade Prostate Cancer: Results from the REDUCE study. [AUA 2011 Annual Meeting]. 2011;185(4 Suppl):e135.
Thomas II J-A, Gerber L, Moreira DM, Banez L, Andriole G, Rittmaster RS, Freedland SJ. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE study. [Cancer Epidemiol Biomarkers Prev]. 2012;21(4):576-81.
Andriole GA, Bostwick D, Gomella L, Marberger M, Montorsi F, Tammela T, Tindall D, Rittmaster RS, Gould I, Garges H, Wilson TH, Castro R.Modeling and analysis of Gleason score 8–10 prostate cancers in the REDUCE study.Urology.2014;84(2):393–399
Aubin SMJ, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184(4):1947-52.
Chenwei Wu; Daniel M. Moreira; Leah Gerber; Roger S. Rittmaster; Gerald L. Andriole; Stephen J. Freedland. DIABETES AND PROSTATE CANCER RISK IN THE REDUCE TRIAL. Prostate Cancer Prostatic Dis. 2011;14(4):326-31.
Claus G. Roehrborn, J. Curtis Nickel, Gerald L. Andriole, R. Paul Gagnier, Libby Black, Tim Wilson, Roger S. Rittmaster . Dutasteride improves the outcomes of benign prostatic hyperplasia: a secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011;73(3):641-6.
David G. Bostwick, Junqi Qian, Krystyna Drewnowska, Stephen Varvel, Kathleen C. Bostwick, Michael Marberger, and Roger S. Rittmaster. REDUCE 4yr: Pathology, RP (Prostate Needle Biopsy Quality in Reduction by Dutasteride of Prostate Cancer Events Study: Worldwide Comparison of Improvement With Investigator Training and Centralized Laboratory Processing). Urology. 2010;75(6):1406-11.
G Andriole, D Bostwick, O Brawley, L Gomella, M Marberger, F Montorsi, C Pettaway, T Tammela, C Teloken, D Tindall, M Somerville, I Fowler and R Rittmaster on behalf of the REDUCE Study Group. Effect of Dutasteride on the Risk of Prostate Cancer. N Engl J Med. 2010;362(13):1192-1202.
Gerald L. Andriole on behalf of the REDUCE study group. The Effect of Dutasteride on the Usefulness of Prostate Specific Antigen for the Diagnosis of High Grade and Clinically Relevant Prostate Cancer in Men With a Previous Negative Biopsy: Results From the REDUCE Study. Journal of Urology. 2011;185(1):126-131.
J. Curtis Nickel, Claus Roehrborn, Francesco Montorsi,Timothy Wilson, Roger S. Rittmaster. DUTASTERIDE REDUCES PROSTATITIS SYMPTOMS COMPARED TO PLACEBO IN MEN ENROLLED IN THE REDUCE (REDUCTION OF DUTASTERIDE IN CANCER EVENTS) STUDY. J Urol. 2011;186(4):1313-1318.
Lucia S, Somerville M, Fowler I, Rittmaster R, Bostwick D. Comparison of classic and International Society of Urological Pathology 2005 Modified Gleason grading using needle biopsies from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Arch Pathol Lab Med. 2013;137(12):1740-6.
Michael Marberger, John D. McConnell, Ivy Fowler, Gerald L. Andriole, David G. Bostwick, Matthew C. Somerville, Roger S. Rittmaster. Biopsy Misidentification Identified by DNA Profiling in a Large Multicenter Trial. J Clin Oncol. 2011;29(13):1744-9.
Michael Marberger, Stephen J. Freedland, Gerald L. Andriole, Mark Emberton, Curtis A. Pettaway, Francesco Montorsi, Claudio Teloken, Roger S. Rittmaster, Matthew Somerville and Ramiro Castro. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int. 2011;109(8):1162-1169.
Michael Marberger, Tim Wilson, Roger Rittmaster. Low serum testosterone levels are poor predictors of sexual dysfunction . BJU Int. 2011;108(2):256-62.
Michael W. Kattan, Stephanie R. Earnshaw, Cheryl L. McDade, Libby K. Black, Gerald L. Andriole. Cost-Effectiveness of Chemoprevention with Dutasteride Based on Results from the REDUCE Clinical Trial . Appl Health Econ Health Policy. 2011;9(5):305-15.
Newcombe PJ, Reck BH, Sun J, Platek GT, Verzill Ci, Karim Kader A, Kim S-T, Jin T, Zhang Z, Zheng SL, Condreay LD et al.. A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk. Genetics Epidemiology. 2012;36(1):71-83.
Sheila M. J. Aubin, Jennifer Reid, Mark J. Sarno, Amy Blase, Jacqueline Aussie, Harry Rittenhouse, Roger S. Rittmaster, Gerald L. Andriole, Jack Groskopf. Prostate Cancer Gene 3 Score Predicts Prostate Biopsy Outcome in Men Receiving Dutasteride for Prevention of Prostate Cancer: Results From the REDUCE Trial . Urology. 2011;78(2):380-5.
Stephen J. Freedland, Leah Gerber, Lionel Banez, Daniel Moreira, Gerald L. Andriole, and Roger S. Rittmaster on behalf of the REDUCE Study Group. Statin Use and the Risk of Prostate Cancer and High-grade Prostate Cancer: Results from the REDUCE study. AUA 2011 Annual Meeting. 2011;185(4 Suppl):e135.
Thomas II J-A, Gerber L, Moreira DM, Banez L, Andriole G, Rittmaster RS, Freedland SJ. Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE study. Cancer Epidemiol Biomarkers Prev. 2012;21(4):576-81.
Medical condition
Neoplasms, Prostate
Product
dutasteride
Collaborators
Not applicable
Study date(s)
March 2003 to May 2009
Type
Interventional
Phase
3
Participation criteria
Sex
Male
Age
50 - 75 years
Accepts healthy volunteers
No
- Informed consent to participate in study.
- Have had a single negative prostate biopsy within 6 months prior to enrollment in study.
- More than one previous negative prostate biopsy.
- History of prostate cancer.
Inclusion and exclusion criteria
Inclusion criteria:
- Informed consent to participate in study.
- Have had a single negative prostate biopsy within 6 months prior to enrollment in study.
- Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a PSA between 3.0 and 10 if over age 60.
- Ability and will to participate in study for 4 years.
Exclusion criteria:
- More than one previous negative prostate biopsy.
- History of prostate cancer.
- Previous prostate surgery.
- Inability to urinate requiring the need of a catheter during the previous 2 years.
- Any condition (other than benign prostatic hypertrophy) which may result in urinary symptoms or changes in urine flow rate.
- Cancer within previous 5 years (other than basal or squamous cell cancers of the skin).
- Any unstable serious medical condition.
- Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride (Avodart), testosterone, or drugs that can block the action of male hormones.
Trial location(s)
Location
GSK Investigational Site
Baltimore, Maryland, United States, 21201
Status
Study Complete
Location
GSK Investigational Site
Mechanicsville, Virginia, United States, 23116
Status
Study Complete
Location
GSK Investigational Site
Ostfildern, Baden-Wuerttemberg, Germany, 73760
Status
Study Complete
Location
GSK Investigational Site
Rochester, New York, United States, 14642
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37232-2765
Status
Study Complete
Location
GSK Investigational Site
Edison, New Jersey, United States, 08837
Status
Study Complete
Location
GSK Investigational Site
Sarasota, Florida, United States, 34237
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Flensburg, Schleswig-Holstein, Germany, 24944
Status
Study Complete
Location
GSK Investigational Site
Hildesheim, Niedersachsen, Germany, 31134
Status
Study Complete
Location
GSK Investigational Site
Richmond Hill, Ontario, Canada, L4C 1T6
Status
Study Complete
Location
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40229
Status
Study Complete
Location
GSK Investigational Site
Buxtehude, Niedersachsen, Germany, 21614
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90059
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pico Rivera, California, United States, 90660
Status
Study Complete
Location
GSK Investigational Site
Krefeld, Nordrhein-Westfalen, Germany, 47799
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bath, Somerset, United Kingdom, BA1 1BX
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90470-340
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63110-2539
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New York, New York, United States, 10021
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Denver, Colorado, United States, 80211
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98166
Status
Study Complete
Location
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40211
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Liverpool, Merseyside, United Kingdom, L7 8XP
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23502
Status
Study Complete
Location
GSK Investigational Site
Columbus, Ohio, United States, 43214
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30342
Status
Study Complete
Location
GSK Investigational Site
Greer, South Carolina, United States, 29651
Status
Study Complete
Location
GSK Investigational Site
Lake Worth, Florida, United States, 33461
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Randwick, New South Wales, Australia, 2031
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98499
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Woodstock, Georgia, United States, 30189
Status
Study Complete
Location
GSK Investigational Site
Rio de Janeiro, Rio De Janeiro, Brazil, 20 551-030
Status
Study Complete
Location
GSK Investigational Site
Hattiesburg, Mississippi, United States, 39401
Status
Study Complete
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45130
Status
Study Complete
Location
GSK Investigational Site
Ribeirão Preto, São Paulo, Brazil, 14085-000
Status
Study Complete
Location
GSK Investigational Site
Laguna Hills, California, United States, 92653
Status
Study Complete
Location
GSK Investigational Site
Clearwater, Florida, United States, 33761
Status
Study Complete
Location
GSK Investigational Site
Hershey, Pennsylvania, United States, 17033-0850
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90048
Status
Study Complete
Location
GSK Investigational Site
Rosemont, Pennsylvania, United States, 19010
Status
Study Complete
Location
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53177
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19053
Status
Study Complete
Location
GSK Investigational Site
Royal Oak, Michigan, United States, 48073
Status
Study Complete
Location
GSK Investigational Site
Edgbaston, Birmingham, United Kingdom, B15 2SQ
Status
Study Complete
Location
GSK Investigational Site
Herzogenaurach, Bayern, Germany, 91074
Status
Study Complete
Location
GSK Investigational Site
Chichester, Sussex West, United Kingdom, PO19 4SE
Status
Study Complete
Location
GSK Investigational Site
Wilkau-Hasslau, Sachsen, Germany, 08112
Status
Study Complete
Location
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45883
Status
Study Complete
Location
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
Status
Study Complete
Location
GSK Investigational Site
Garmisch-Partenkirchen, Bayern, Germany, 82467
Status
Study Complete
Location
GSK Investigational Site
Tamarac, Florida, United States, 33321
Status
Study Complete
Location
GSK Investigational Site
Ragusa (CT), Sicilia, Italy, 97100
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Okeechobee, Florida, United States, 34972
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Fresno, California, United States, 93720
Status
Study Complete
Location
GSK Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30140-073
Status
Study Complete
Location
GSK Investigational Site
Nuernberg, Bayern, Germany, 90489
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ribnitz-Damgarten, Mecklenburg-Vorpommern, Germany, 18311
Status
Study Complete
Location
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile
Status
Study Complete
Location
GSK Investigational Site
Longwood, Florida, United States, 32750
Status
Study Complete
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28211
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Edina, Minnesota, United States, 55435
Status
Study Complete
Location
GSK Investigational Site
Waldkirch, Baden-Wuerttemberg, Germany, 79183
Status
Study Complete
Location
GSK Investigational Site
East Syracuse, New York, United States, 13057
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Seattle, Washington, United States, 98133
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72205
Status
Study Complete
Location
GSK Investigational Site
Raleigh, North Carolina, United States, 27607
Status
Study Complete
Location
GSK Investigational Site
Delray Beach, Florida, United States, 33484
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Durham, North Carolina, United States, 27710
Status
Study Complete
Location
GSK Investigational Site
Detroit, Michigan, United States, 48202
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Zapopan, Jalisco, Jalisco, Mexico, 45100
Status
Study Complete
Location
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23552
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Paderborn, Nordrhein-Westfalen, Germany, 33098
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Borken, Nordrhein-Westfalen, Germany, 46325
Status
Study Complete
Location
GSK Investigational Site
Overland Park, Kansas, United States, 66211
Status
Study Complete
Location
GSK Investigational Site
Fayetteville, Georgia, United States, 30214
Status
Study Complete
Location
GSK Investigational Site
Evansville, Indiana, United States, 47714
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Diego, California, United States, 92120
Status
Study Complete
Location
GSK Investigational Site
Wuppertal, Nordrhein-Westfalen, Germany, 42103
Status
Study Complete
Location
GSK Investigational Site
Billings, Montana, United States, 59102
Status
Study Complete
Location
GSK Investigational Site
CAPELLE AAN DEN IJSSEL, Netherlands, 2906 ZC
Status
Study Complete
Location
GSK Investigational Site
Albany, New York, United States, 12208
Status
Study Complete
Location
GSK Investigational Site
Gretna, Louisiana, United States, 70056
Status
Study Complete
Location
GSK Investigational Site
Fountain Valley, California, United States, 92708
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Watertown, Massachusetts, United States, 02472
Status
Study Complete
Location
GSK Investigational Site
Wismar, Mecklenburg-Vorpommern, Germany, 23970
Status
Study Complete
Location
GSK Investigational Site
Longmont, Colorado, United States, 80501
Status
Study Complete
Location
GSK Investigational Site
Edinburgh, Midlothian, United Kingdom, EH4 2XU
Status
Study Complete
Location
GSK Investigational Site
Great Neck, New York, United States, 11021
Status
Study Complete
Location
GSK Investigational Site
Kelkheim, Hessen, Germany, 65779
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Maywood, Illinois, United States, 60153
Status
Study Complete
Location
GSK Investigational Site
Aventura, Florida, United States, 33180
Status
Study Complete
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85014
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Walnut Creek, California, United States, 94598
Status
Terminated/Withdrawn
Location
GSK Investigational Site
La Mesa, California, United States, 91942
Status
Study Complete
Location
GSK Investigational Site
Long Beach, California, United States, 90806
Status
Study Complete
Location
GSK Investigational Site
Harrisburg, Pennsylvania, United States, 17110
Status
Study Complete
Location
GSK Investigational Site
Southampton, Hampshire, United Kingdom, SO16 6YD
Status
Study Complete
Location
GSK Investigational Site
Aachen, Nordrhein-Westfalen, Germany, 52078
Status
Study Complete
Location
GSK Investigational Site
Graham, Washington, United States, 98338
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Shreveport, Louisiana, United States, 71106
Status
Study Complete
Location
GSK Investigational Site
Bad Doberan, Mecklenburg-Vorpommern, Germany, 18209
Status
Study Complete
Location
GSK Investigational Site
West Orange, New Jersey, United States, 07052
Status
Study Complete
Location
GSK Investigational Site
Ayr, Ayrshire, United Kingdom, KA6 6DX
Status
Study Complete
Location
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47051
Status
Study Complete
Location
GSK Investigational Site
Charlotte, NC 28207, North Carolina, United States, 28207
Status
Study Complete
Location
GSK Investigational Site
Newport Beach, California, United States, 92660
Status
Study Complete
Location
GSK Investigational Site
Ruston, Louisiana, United States, 71270
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Orchard Park, New York, United States, 14127
Status
Study Complete
Location
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
Status
Study Complete
Location
GSK Investigational Site
Oregon City, Oregon, United States, 97045
Status
Study Complete
Location
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
Status
Study Complete
Location
GSK Investigational Site
Milford, Massachusetts, United States, 01757
Status
Study Complete
Location
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23562
Status
Study Complete
Location
GSK Investigational Site
Braunschweig, Niedersachsen, Germany, 38120
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Gardelegen, Sachsen-Anhalt, Germany, 39638
Status
Study Complete
Location
GSK Investigational Site
Haverhill, Massachusetts, United States, 01830
Status
Study Complete
Location
GSK Investigational Site
Galesburg, Illinois, United States, 61401
Status
Study Complete
Location
GSK Investigational Site
Fredericton, New Brunswick, Canada, E3B 5B8
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76104
Status
Study Complete
Location
GSK Investigational Site
Reno, Nevada, United States, 89502
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Buchholz, Niedersachsen, Germany, 21244
Status
Study Complete
Location
GSK Investigational Site
Redhill, Surrey, United Kingdom, RH1 5RH
Status
Study Complete
Location
GSK Investigational Site
Isola della Scala (VR), Veneto, Italy, 37063
Status
Study Complete
Location
GSK Investigational Site
Braintree, Massachusetts, United States, 02184
Status
Study Complete
Location
GSK Investigational Site
Wolfsburg, Niedersachsen, Germany, 38440
Status
Study Complete
Location
GSK Investigational Site
Cary, North Carolina, United States, 27511
Status
Study Complete
Location
GSK Investigational Site
Aurora, Colorado, United States, 80012
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Warwickshire, United Kingdom, B9 5SS
Status
Study Complete
Location
GSK Investigational Site
Fort Wayne, Indiana, United States, 46825
Status
Study Complete
Location
GSK Investigational Site
Alexandria, Virginia, United States, 22302
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Sellersville, Pennsylvania, United States, 18960
Status
Study Complete
Location
GSK Investigational Site
Greenfield Park, Québec, Canada, J4V 2H3
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22299
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Braunschweig, Niedersachsen, Germany, 38100
Status
Study Complete
Location
GSK Investigational Site
Leicester, Leicestershire, United Kingdom, LE5 4PW
Status
Study Complete
Location
GSK Investigational Site
Towson, Maryland, United States, 21204
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63141
Status
Study Complete
Location
GSK Investigational Site
Fairfax, Virginia, United States, 22031
Status
Study Complete
Location
GSK Investigational Site
Minneapolis, Minnesota, United States, 55404
Status
Study Complete
Location
GSK Investigational Site
Charleston, South Carolina, United States, 29425
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53209
Status
Study Complete
Location
GSK Investigational Site
Englewood, Colorado, United States, 80113
Status
Study Complete
Location
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, 1437
Status
Study Complete
Location
GSK Investigational Site
Clydebank, Glasgow, United Kingdom, G81 2DR
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60640
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98195
Status
Study Complete
Location
GSK Investigational Site
Koblenz, Rheinland-Pfalz, Germany, 56068
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bruchsal, Baden-Wuerttemberg, Germany, 76646
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32257
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Duesseldorf, Nordrhein-Westfalen, Germany, 40470
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Garden City, New York, United States, 11530
Status
Study Complete
Location
GSK Investigational Site
Kleinblittersdorf, Baden-Wuerttemberg, Germany, 66271
Status
Study Complete
Location
GSK Investigational Site
Upland, California, United States, 91786
Status
Study Complete
Location
GSK Investigational Site
Memphis, Tennessee, United States, 38119
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10016
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bocholt, Nordrhein-Westfalen, Germany, 46399
Status
Study Complete
Location
GSK Investigational Site
Nashville, Tennessee, United States, 37209
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Reading, Berkshire, United Kingdom, RG2 0TG
Status
Study Complete
Location
GSK Investigational Site
Germantown, Tennessee, United States, 38138
Status
Study Complete
Location
GSK Investigational Site
Zanesville, Ohio, United States, 43701
Status
Study Complete
Location
GSK Investigational Site
Schleswig, Schleswig-Holstein, Germany, 24837
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98122
Status
Study Complete
Location
GSK Investigational Site
Newcastle Upon Tyne, Northumberland, United Kingdom, NE7 7DN
Status
Study Complete
Location
GSK Investigational Site
Dortmund, Nordrhein-Westfalen, Germany, 44137
Status
Study Complete
Location
GSK Investigational Site
Temecula, California, United States, 92591
Status
Study Complete
Location
GSK Investigational Site
Lebanon, New Hampshire, United States, 03756
Status
Terminated/Withdrawn
Location
GSK Investigational Site
West Palm Beach, Florida, United States, 33409
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45219
Status
Study Complete
Location
GSK Investigational Site
Bad Schoenborn, Baden-Wuerttemberg, Germany, 76669
Status
Study Complete
Location
GSK Investigational Site
Torrance, California, United States, 90505
Status
Study Complete
Location
GSK Investigational Site
Harrisonburg, Virginia, United States, 22801
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18109
Status
Study Complete
Location
GSK Investigational Site
Rochester, Minnesota, United States, 55905
Status
Study Complete
Location
GSK Investigational Site
Rheinfelden, Baden-Wuerttemberg, Germany, 79618
Status
Study Complete
Location
GSK Investigational Site
South Burlington, Vermont, United States, 05403
Status
Study Complete
Location
GSK Investigational Site
State College, Pennsylvania, United States, 16801
Status
Study Complete
Location
GSK Investigational Site
Orlando, Florida, United States, 32803
Status
Study Complete
Location
GSK Investigational Site
Dallas, Texas, United States, 75230
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Charlottesville, Virginia, United States, 22911
Status
Study Complete
Location
GSK Investigational Site
Waterloo, Liverpool, United Kingdom, L22 0LG
Status
Study Complete
Location
GSK Investigational Site
Coventry, Warwickshire, United Kingdom, CV1 2TZ
Status
Study Complete
Location
GSK Investigational Site
Stanford, California, United States, 94305
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New Port Richey, Florida, United States, 34652
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ludwigslust, Mecklenburg-Vorpommern, Germany, 19288
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Clearwater, Florida, United States, 33756
Status
Study Complete
Location
GSK Investigational Site
Jeffersonville, Indiana, United States, 47130
Status
Study Complete
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
Status
Study Complete
Location
GSK Investigational Site
Springfield, Missouri, United States, 65807
Status
Study Complete
Location
GSK Investigational Site
Orange, California, United States, 92869
Status
Study Complete
Location
GSK Investigational Site
Stockport, Cheshire, United Kingdom, SK2 7JE
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15215
Status
Study Complete
Location
GSK Investigational Site
West Yarmouth, Massachusetts, United States, 02673
Status
Study Complete
Location
GSK Investigational Site
Staten Island, New York, United States, 10304
Status
Study Complete
Location
GSK Investigational Site
Fort Pierre, South Dakota, United States, 57501
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Newton, Pennsylvania, United States, 18940
Status
Study Complete
Location
GSK Investigational Site
Spokane, Washington, United States, 99202
Status
Study Complete
Location
GSK Investigational Site
San Francisco, California, United States, 94108
Status
Study Complete
Location
GSK Investigational Site
Erkrath, Nordrhein-Westfalen, Germany, 40699
Status
Study Complete
Location
GSK Investigational Site
Tallahassee, Florida, United States, 32308
Status
Study Complete
Location
GSK Investigational Site
Freiburg, Baden-Wuerttemberg, Germany, 79106
Status
Study Complete
Location
GSK Investigational Site
Surrey, British Columbia, Canada, V3V 1N1
Status
Study Complete
Location
GSK Investigational Site
Wocester, Massachusetts, United States, 01608
Status
Study Complete
Location
GSK Investigational Site
Margate, Florida, United States, 33063
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, California, United States, 90073
Status
Study Complete
Location
GSK Investigational Site
Endwell, New York, United States, 13760
Status
Study Complete
Location
GSK Investigational Site
Bad Ems, Rheinland-Pfalz, Germany, 56130
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Lancs, Lancashire, United Kingdom, PR7 1PP
Status
Study Complete
Location
GSK Investigational Site
Fort Myers, Florida, United States, 33916
Status
Study Complete
Location
GSK Investigational Site
Bahia Blanca, Buenos Aires, Argentina, 8001
Status
Study Complete
Location
GSK Investigational Site
Augusta, Georgia, United States, 30912
Status
Study Complete
Location
GSK Investigational Site
Simpsonville, South Carolina, United States, 29681
Status
Study Complete
Location
GSK Investigational Site
Eisleben, Sachsen-Anhalt, Germany, 06295
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19152
Status
Study Complete
Location
GSK Investigational Site
Raleigh, North Carolina, United States, 27612
Status
Study Complete
Location
GSK Investigational Site
Orange Park, Florida, United States, 32073
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Portland, Oregon, United States, 97205
Status
Study Complete
Location
GSK Investigational Site
Dessau, Sachsen-Anhalt, Germany, 06844
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22303
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89106
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Westchester, California, United States, 90045
Status
Study Complete
Location
GSK Investigational Site
Kogarah, New South Wales, Australia, 2217
Status
Study Complete
Location
GSK Investigational Site
Winston-Salem, North Carolina, United States, 27103
Status
Study Complete
Location
GSK Investigational Site
Dierdorf, Rheinland-Pfalz, Germany, 56269
Status
Study Complete
Location
GSK Investigational Site
Wesseling, Nordrhein-Westfalen, Germany, 50389
Status
Study Complete
Location
GSK Investigational Site
Leipzig, Sachsen, Germany, 04105
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, California, United States, 90033
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Atherton, California, United States, 94027
Status
Study Complete
Location
GSK Investigational Site
Nieder-Olm, Rheinland-Pfalz, Germany, 55268
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Bautzen, Sachsen, Germany, 02625
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Buckshaw Village, Chorley, Lancashire, United Kingdom, PR7 7NA
Status
Study Complete
Location
GSK Investigational Site
Birmingham, Alabama, United States, 35209
Status
Study Complete
Location
GSK Investigational Site
Aurora, Colorado, United States, 80010
Status
Study Complete
Location
GSK Investigational Site
Oberhausen, Nordrhein-Westfalen, Germany, 46045
Status
Study Complete
Location
GSK Investigational Site
Waltham, Massachusetts, United States, 02453
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Diego, California, United States, 92128
Status
Study Complete
Location
GSK Investigational Site
Lancaster, Pennsylvania, United States, 17601
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
Status
Study Complete
Location
GSK Investigational Site
Washington, District of Columbia, United States, 20307-5001
Status
Study Complete
Location
GSK Investigational Site
Hennigsdorf, Brandenburg, Germany, 16761
Status
Study Complete
Location
GSK Investigational Site
Coeur d'Alene, Idaho, United States, 83814
Status
Study Complete
Location
GSK Investigational Site
Strausberg, Brandenburg, Germany, 15344
Status
Study Complete
Location
GSK Investigational Site
Middlebury, Connecticut, United States, 06762
Status
Study Complete
Location
GSK Investigational Site
Annapolis, Maryland, United States, 21401
Status
Study Complete
Location
GSK Investigational Site
West Warwick, Rhode Island, United States, 02893
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Leytonstone, London, United Kingdom, E11 1NR
Status
Study Complete
Location
GSK Investigational Site
Salt Lake City, Utah, United States, 84107
Status
Study Complete
Location
GSK Investigational Site
Greenville, North Carolina, United States, 27834
Status
Study Complete
Location
GSK Investigational Site
Springfield, Oregon, United States, 97477
Status
Study Complete
Location
GSK Investigational Site
Salinas, California, United States, 93901
Status
Study Complete
Location
GSK Investigational Site
Marietta, Georgia, United States, 30060
Status
Study Complete
Location
GSK Investigational Site
Plantation, Florida, United States, 33317
Status
Study Complete
Location
GSK Investigational Site
Av Córdoba 2424, Buenos Aires, Argentina, 1120
Status
Study Complete
Location
GSK Investigational Site
Knoxville, Tennessee, United States, 37920
Status
Study Complete
Location
GSK Investigational Site
Kansas City, Missouri, United States, 64114
Status
Study Complete
Location
GSK Investigational Site
Springfield, Illinois, United States, 62781
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Brooklyn, New York, United States, 11234
Status
Study Complete
Location
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73112
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Binghamton, New York, United States, 13901
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Los Angeles, California, United States, 90024
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Columbus, Ohio, United States, 43235
Status
Terminated/Withdrawn
Location
GSK Investigational Site
St. Cloud, Minnesota, United States, 56303
Status
Study Complete
Location
GSK Investigational Site
Goettingen, Niedersachsen, Germany, 37073
Status
Study Complete
Location
GSK Investigational Site
Syracuse, New York, United States, 13210
Status
Study Complete
Location
GSK Investigational Site
Ploen, Schleswig-Holstein, Germany, 24306
Status
Study Complete
Location
GSK Investigational Site
Irvine, California, United States, 92618
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Poca City, Oklahoma, United States, 74601
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60612
Status
Study Complete
Location
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47179
Status
Study Complete
Location
GSK Investigational Site
Trois Rivieres, Québec, Canada, G9A 3V7
Status
Study Complete
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00909-1711
Status
Study Complete
Location
GSK Investigational Site
Concord, North Carolina, United States, 28025
Status
Study Complete
Location
GSK Investigational Site
Cary, North Carolina, United States, 27518
Status
Study Complete
Location
GSK Investigational Site
Neckargemuend, Baden-Wuerttemberg, Germany, 69151
Status
Study Complete
Location
GSK Investigational Site
Sun City, Arizona, United States, 85375
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50969
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19141
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kelowna, British Columbia, Canada, V1Y 2H4
Status
Study Complete
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70121
Status
Study Complete
Location
GSK Investigational Site
Melbourne, Florida, United States, 32901
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Wolmirstedt, Sachsen-Anhalt, Germany, 39326
Status
Study Complete
Location
GSK Investigational Site
Virginia Beach, Virginia, United States, 23454
Status
Study Complete
Location
GSK Investigational Site
Westmead, New South Wales, Australia, 2145
Status
Study Complete
Location
GSK Investigational Site
Moers, Nordrhein-Westfalen, Germany, 47445
Status
Study Complete
Location
GSK Investigational Site
Huntsville, Alabama, United States, 35801
Status
Study Complete
Location
GSK Investigational Site
Lauenburg, Schleswig-Holstein, Germany, 21481
Status
Study Complete
Location
GSK Investigational Site
Senftenberg, Brandenburg, Germany, 01968
Status
Study Complete
Location
GSK Investigational Site
Oldham, Lancashire, United Kingdom, OL1 2JH
Status
Study Complete
Location
GSK Investigational Site
Weissenfels, Sachsen-Anhalt, Germany, 06667
Status
Study Complete
Location
GSK Investigational Site
Kankakee, Illinois, United States, 60901
Status
Study Complete
Location
GSK Investigational Site
Bismarck, North Dakota, United States, 58501
Status
Study Complete
Location
GSK Investigational Site
Cranston, Rhode Island, United States, 02920
Status
Study Complete
Location
GSK Investigational Site
Pointe-Claire, Québec, Canada, H9R 4S3
Status
Study Complete
Location
GSK Investigational Site
Madison, Wisconsin, United States, 53715
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Châlons-En-Champagne, France, 51000
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kansas City, Kansas, United States, 66160
Status
Study Complete
Location
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M41 5SL
Status
Study Complete
Location
GSK Investigational Site
Glasgow, Lanarkshire, United Kingdom, G51 4TF
Status
Study Complete
Location
GSK Investigational Site
Springfield, Massachusetts, United States, 01107
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Owings Mills, Maryland, United States, 21117
Status
Study Complete
Location
GSK Investigational Site
Kamp-Lintfort, Nordrhein-Westfalen, Germany, 47475
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30308
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39104
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45127
Status
Study Complete
Location
GSK Investigational Site
Itzehoe, Schleswig-Holstein, Germany, 25524
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Poughkeepsie, New York, United States, 12601
Status
Study Complete
Location
GSK Investigational Site
Greenville, South Carolina, United States, 29650
Status
Study Complete
Location
GSK Investigational Site
Chaska, Minnesota, United States, 55318
Status
Study Complete
Location
GSK Investigational Site
Neumuenster, Schleswig-Holstein, Germany, 24534
Status
Study Complete
Location
GSK Investigational Site
Salzgitter, Niedersachsen, Germany, 38226
Status
Study Complete
Location
GSK Investigational Site
Liverpool, Merseyside, United Kingdom, L1 9AD
Status
Study Complete
Location
GSK Investigational Site
Victoria, British Columbia, Canada, V8V 3N1
Status
Study Complete
Location
GSK Investigational Site
Niagara Falls, Ontario, Canada, L2E 6A6
Status
Study Complete
Location
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, 1425
Status
Study Complete
Location
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47198
Status
Study Complete
Location
GSK Investigational Site
Trumbull, Connecticut, United States, 06611
Status
Study Complete
Location
GSK Investigational Site
Husum, Schleswig-Holstein, Germany, 25813
Status
Study Complete
Location
GSK Investigational Site
Woolloongabba, Queensland, Australia, 4102
Status
Study Complete
Location
GSK Investigational Site
Victoria, British Columbia, Canada, V8T 5G1
Status
Study Complete
Location
GSK Investigational Site
Saint John, New Brunswick, Canada, E2L 3J8
Status
Study Complete
Location
GSK Investigational Site
Schwarzenberg, Sachsen, Germany, 08340
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32216
Status
Study Complete
Location
GSK Investigational Site
Ponce, Puerto Rico, Puerto Rico, 00716
Status
Study Complete
Location
GSK Investigational Site
Roswell, Georgia, United States, 30076
Status
Study Complete
Location
GSK Investigational Site
Santa Monica, California, United States, 90404
Status
Study Complete
Location
GSK Investigational Site
Plymouth, Devon, United Kingdom, PL6 8DH
Status
Study Complete
Location
GSK Investigational Site
Chapel Hill, North Carolina, United States, 27599-7600
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Voorhees, New Jersey, United States, 08043
Status
Study Complete
Location
GSK Investigational Site
San Ramon, California, United States, 94583
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Ganderkesee, Niedersachsen, Germany, 27777
Status
Study Complete
Location
GSK Investigational Site
Arlington, Texas, United States, 76017
Status
Study Complete
Location
GSK Investigational Site
Jacksonville, Florida, United States, 32224
Status
Study Complete
Location
GSK Investigational Site
Kippa Ring, Queensland, Australia, 4021
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98431
Status
Study Complete
Location
GSK Investigational Site
Providence, Rhode Island, United States, 02904
Status
Study Complete
Location
GSK Investigational Site
St. Joseph, Michigan, United States, 49085
Status
Study Complete
Location
GSK Investigational Site
Mather, California, United States, 95655
Status
Study Complete
Location
GSK Investigational Site
Ann Arbor, Michigan, United States, 48106
Status
Study Complete
Location
GSK Investigational Site
Newton, Massachusetts, United States, 2462
Status
Study Complete
Location
GSK Investigational Site
Monroeville, Pennsylvania, United States, 15146
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60616
Status
Study Complete
Location
GSK Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany, 18069
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Arnsberg, Nordrhein-Westfalen, Germany, 59821
Status
Study Complete
Location
GSK Investigational Site
Muelheim, Nordrhein-Westfalen, Germany, 45475
Status
Study Complete
Location
GSK Investigational Site
Fort Worth, Texas, United States, 76107
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45212
Status
Study Complete
Location
GSK Investigational Site
Tauton, Somerset, United Kingdom, TA1 5DA
Status
Study Complete
Location
GSK Investigational Site
Holzminden, Niedersachsen, Germany, 37603
Status
Study Complete
Location
GSK Investigational Site
Backnang, Baden-Wuerttemberg, Germany, 71522
Status
Study Complete
Location
GSK Investigational Site
Norwich, Norfolk, United Kingdom, NR4 7FP
Status
Study Complete
Location
GSK Investigational Site
Encino, California, United States, 91316
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30309
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80220
Status
Study Complete
Location
GSK Investigational Site
Van Nuys, California, United States, 91405
Status
Study Complete
Location
GSK Investigational Site
São Paulo, São Paulo, Brazil, 04122-000
Status
Study Complete
Location
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19057
Status
Study Complete
Location
GSK Investigational Site
Cheyenne, Wyoming, United States, 82001
Status
Study Complete
Location
GSK Investigational Site
Lafayette, Louisiana, United States, 70503
Status
Study Complete
Location
GSK Investigational Site
Las Vegas, Nevada, United States, 89148
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103-6204
Status
Study Complete
Location
GSK Investigational Site
Hettstedt, Sachsen-Anhalt, Germany, 06333
Status
Study Complete
Location
GSK Investigational Site
Stoke-on-Trent, Staffordshire, United Kingdom, ST4 6QG
Status
Study Complete
Location
GSK Investigational Site
Exeter, Devon, United Kingdom, EX2 5DW
Status
Study Complete
Location
GSK Investigational Site
Jackson, Mississippi, United States, 39202
Status
Study Complete
Location
GSK Investigational Site
Sacramento, California, United States, 95816
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Panama City, Florida, United States, 32405
Status
Study Complete
Location
GSK Investigational Site
St. Louis, Missouri, United States, 63136
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98101
Status
Study Complete
Location
GSK Investigational Site
Ahrensburg, Schleswig-Holstein, Germany, 22926
Status
Study Complete
Location
GSK Investigational Site
San Bernardino, California, United States, 92404
Status
Study Complete
Location
GSK Investigational Site
Honolulu, Hawaii, United States, 96813
Status
Study Complete
Location
GSK Investigational Site
Oranienburg, Brandenburg, Germany, 16515
Status
Study Complete
Location
GSK Investigational Site
Hemmoor, Schleswig-Holstein, Germany, 21745
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZD
Status
Study Complete
Location
GSK Investigational Site
Langenfeld, Nordrhein-Westfalen, Germany, 40764
Status
Study Complete
Location
GSK Investigational Site
Bremervoerde, Niedersachsen, Germany, 27432
Status
Study Complete
Location
GSK Investigational Site
Stevenage, Hertfordshire, United Kingdom, SG2 4AB
Status
Study Complete
Location
GSK Investigational Site
Elmont, New York, United States, 11003
Status
Study Complete
Location
GSK Investigational Site
Chemnitz, Sachsen, Germany, 09126
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Portland, Oregon, United States, 97213
Status
Study Complete
Location
GSK Investigational Site
Wolverhampton, United Kingdom, WV10 9RU
Status
Study Complete
Location
GSK Investigational Site
New Britain, Connecticut, United States, 06052
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15232
Status
Study Complete
Location
GSK Investigational Site
Texarkana, Texas, United States, 75503
Status
Study Complete
Location
GSK Investigational Site
Hackensack, New Jersey, United States, 07601
Status
Study Complete
Location
GSK Investigational Site
Mannheim, Baden-Wuerttemberg, Germany, 68307
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19144
Status
Study Complete
Location
GSK Investigational Site
Scottsdale, Arizona, United States, 85258
Status
Study Complete
Location
GSK Investigational Site
Dessau, Sachsen-Anhalt, Germany, 06842
Status
Study Complete
Location
GSK Investigational Site
Culver City, California, United States, 90232
Status
Study Complete
Location
GSK Investigational Site
Lancaster, Pennsylvania, United States, 17604
Status
Study Complete
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02115
Status
Study Complete
Location
GSK Investigational Site
Bad Schwartau, Schleswig-Holstein, Germany, 23611
Status
Study Complete
Location
GSK Investigational Site
Bristol, Gloucestershire, United Kingdom, BS10 5NB
Status
Study Complete
Location
GSK Investigational Site
Portland, Oregon, United States, 97210
Status
Study Complete
Location
GSK Investigational Site
Naumburg, Sachsen-Anhalt, Germany, 06618
Status
Study Complete
Location
GSK Investigational Site
Duelmen, Nordrhein-Westfalen, Germany, 48249
Status
Study Complete
Location
GSK Investigational Site
Greenbelt, Maryland, United States, 20770
Status
Study Complete
Location
GSK Investigational Site
Metairie, Louisiana, United States, 70001
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Pulheim, Nordrhein-Westfalen, Germany, 50259
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Little Rock, Arkansas, United States, 72211
Status
Study Complete
Location
GSK Investigational Site
Poway, California, United States, 92064
Status
Study Complete
Location
GSK Investigational Site
Esslingen, Baden-Wuerttemberg, Germany, 73728
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Portsmouth, Hampshire, United Kingdom, PO3 6AD
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Marlton, New Jersey, United States, 08053
Status
Study Complete
Location
GSK Investigational Site
Bala Cynwyd, Pennsylvania, United States, 19004
Status
Study Complete
Location
GSK Investigational Site
Rosario, Santa Fe, Argentina, 2000
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Perth Amboy, New Jersey, United States, 08861
Status
Study Complete
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85032
Status
Study Complete
Location
GSK Investigational Site
Hartford, Connecticut, United States, 06106
Status
Study Complete
Location
GSK Investigational Site
Hamburg, Hamburg, Germany, 22767
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Anchorage, Alaska, United States, 99508
Status
Study Complete
Location
GSK Investigational Site
Camp Hill, Pennsylvania, United States, 17011
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Covington, Louisiana, United States, 70433
Status
Study Complete
Location
GSK Investigational Site
Bad Bergzabern, Rheinland-Pfalz, Germany, 76887
Status
Study Complete
Location
GSK Investigational Site
Rockville, Maryland, United States, 20850
Status
Study Complete
Location
GSK Investigational Site
Lawrencevill, New Jersey, United States, 08648
Status
Study Complete
Location
GSK Investigational Site
St. Petersburg, Florida, United States, 33703
Status
Study Complete
Location
GSK Investigational Site
Myrtle Beach, South Carolina, United States, 29572
Status
Study Complete
Location
GSK Investigational Site
Bryn Mawr, Pennsylvania, United States, 19010
Status
Study Complete
Location
GSK Investigational Site
Houma, Louisiana, United States, 70360
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Kempen, Nordrhein-Westfalen, Germany, 47906
Status
Study Complete
Location
GSK Investigational Site
Periohi Dragana, Alexandroupolis, Greece, 68100
Status
Study Complete
Location
GSK Investigational Site
Greensboro, North Carolina, United States, 27403
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Charlotte, North Carolina, United States, 28262
Status
Study Complete
Location
GSK Investigational Site
Wiesbaden, Hessen, Germany, 65185
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Status
Study Complete
Location
GSK Investigational Site
La Laguna (Santa Cruz de Tenerife), Spain, 38320
Status
Study Complete
Location
GSK Investigational Site
Krefeld, Nordrhein-Westfalen, Germany, 47805
Status
Study Complete
Location
GSK Investigational Site
Cardiff, Glamorgan, United Kingdom, CF14 5GJ
Status
Study Complete
Location
GSK Investigational Site
Lexington, Kentucky, United States, 40508
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Henderson, Nevada, United States, 89014
Status
Study Complete
Location
GSK Investigational Site
Anaheim, California, United States, 92801
Status
Study Complete
Location
GSK Investigational Site
Melrose Park, Illinois, United States, 60160
Status
Study Complete
Location
GSK Investigational Site
Phoenix, Arizona, United States, 85023
Status
Study Complete
Location
GSK Investigational Site
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Status
Study Complete
Location
GSK Investigational Site
Miramichi, New Brunswick, Canada, E1V 1N9
Status
Study Complete
Location
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
Status
Study Complete
Location
GSK Investigational Site
Waltershausen, Thueringen, Germany, 99880
Status
Study Complete
Location
GSK Investigational Site
San Diego, California, United States, 92103
Status
Study Complete
Location
GSK Investigational Site
Mineola, New York, United States, 11501
Status
Study Complete
Location
GSK Investigational Site
South Daytona, Florida, United States, 32119
Status
Study Complete
Location
GSK Investigational Site
Kiel, Schleswig-Holstein, Germany, 24143
Status
Study Complete
Location
GSK Investigational Site
Homewood, Alabama, United States, 35209
Status
Study Complete
Location
GSK Investigational Site
Marl, Nordrhein-Westfalen, Germany, 45770
Status
Study Complete
Location
GSK Investigational Site
Manchester, Lancashire, United Kingdom, M8 5RB
Status
Study Complete
Location
GSK Investigational Site
Richmond, Virginia, United States, 23249
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60637
Status
Study Complete
Location
GSK Investigational Site
Koenigswinter, Nordrhein-Westfalen, Germany, 53639
Status
Terminated/Withdrawn
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70119
Status
Terminated/Withdrawn
Location
GSK Investigational Site
San Francisco, California, United States, 94121
Status
Study Complete
Location
GSK Investigational Site
Gelsenkirchen, Nordrhein-Westfalen, Germany, 45894
Status
Study Complete
Location
GSK Investigational Site
Darlinghurst, New South Wales, Australia, 2010
Status
Study Complete
Location
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico, 00921-3201
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2009-11-05
Actual study completion date
2009-11-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website